Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Increased Susceptibility of the CD57 - NK Cells Expressing KIR2DL2/3 and NKG2C to iCasp9 Gene Retroviral Transduction and the Relationships with Proliferative Potential, Activation Degree, and Death Induction Response.

Tytuł:
Increased Susceptibility of the CD57 NK Cells Expressing KIR2DL2/3 and NKG2C to iCasp9 Gene Retroviral Transduction and the Relationships with Proliferative Potential, Activation Degree, and Death Induction Response.
Autorzy:
Palamarchuk AI; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Alekseeva NA; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Streltsova MA; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Ustiuzhanina MO; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.; Center of Life Sciences, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia.
Kobyzeva PA; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Kust SA; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Grechikhina MV; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Boyko AA; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Shustova OA; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Sapozhnikov AM; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Kovalenko EI; Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Dec 11; Vol. 22 (24). Date of Electronic Publication: 2021 Dec 11.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
CRISPR-Cas Systems*
Cell Proliferation*
Gene Expression Regulation*
Genetic Vectors*
Lymphocyte Activation*
Retroviridae*
Transduction, Genetic*
NK Cell Lectin-Like Receptor Subfamily C/*biosynthesis
Receptors, KIR2DL2/*biosynthesis
Receptors, KIR2DL3/*biosynthesis
Cell Death ; Humans ; K562 Cells ; Killer Cells, Natural ; NK Cell Lectin-Like Receptor Subfamily C/genetics ; Receptors, KIR2DL2/genetics ; Receptors, KIR2DL3/genetics
References:
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9150-5. (PMID: 10908661)
J Exp Med. 2017 Feb;214(2):491-510. (PMID: 28057804)
Cancers (Basel). 2019 Jun 03;11(6):. (PMID: 31163679)
Viruses. 2019 Mar 12;11(3):. (PMID: 30870969)
Nat Rev Immunol. 2008 Apr;8(4):259-68. (PMID: 18340344)
Front Pharmacol. 2014 Nov 27;5:254. (PMID: 25505885)
J Immunol. 2013 Oct 15;191(8):3981-5. (PMID: 24038086)
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3655-60. (PMID: 9520421)
Cell Death Differ. 2018 Mar;25(3):486-541. (PMID: 29362479)
Front Immunol. 2020 Aug 07;11:1965. (PMID: 32903482)
PLoS One. 2018 Dec 5;13(12):e0208469. (PMID: 30517188)
Biomedicines. 2021 Jun 09;9(6):. (PMID: 34207853)
Stem Cells. 2010 Jun;28(6):1107-15. (PMID: 20506146)
Eur J Immunol. 2012 Feb;42(2):447-57. (PMID: 22105371)
Gene Ther. 1997 Apr;4(4):303-8. (PMID: 9176515)
Trends Immunol. 2016 Jul;37(7):451-461. (PMID: 27160662)
J Exp Med. 1990 May 1;171(5):1509-26. (PMID: 1692080)
Nat Commun. 2019 Sep 2;10(1):3931. (PMID: 31477722)
Stem Cells. 2015 Jan;33(1):91-100. (PMID: 25330775)
PLoS One. 2012;7(1):e30264. (PMID: 22279576)
Int J Mol Sci. 2016 Oct 27;17(11):. (PMID: 27801784)
Clin Transl Immunology. 2014 Jun 20;3(6):e17. (PMID: 25505965)
Clin Exp Immunol. 2018 Sep;193(3):265-274. (PMID: 29737525)
J Immunol. 2014 Apr 15;192(8):3889-97. (PMID: 24634493)
Front Immunol. 2019 Apr 03;10:687. (PMID: 31001281)
J Immunol Res. 2018 Sep 17;2018:4054815. (PMID: 30306093)
Front Immunol. 2019 Aug 02;10:1812. (PMID: 31428098)
Blood. 2005 Jun 1;105(11):4247-54. (PMID: 15728125)
Int J Cancer. 2019 Oct 1;145(7):1935-1945. (PMID: 30860598)
Blood. 2001 Mar 1;97(5):1249-57. (PMID: 11222367)
Oncotarget. 2017 Apr 4;8(14):23996-24008. (PMID: 28177918)
Curr Pharm Biotechnol. 2021 Aug 19;:. (PMID: 34414871)
Blood. 2013 Apr 4;121(14):2678-88. (PMID: 23325834)
Hum Gene Ther Methods. 2012 Dec;23(6):376-86. (PMID: 23186165)
Immunol Cell Biol. 2018 Feb;96(2):212-228. (PMID: 29363179)
Leukemia. 2018 Feb;32(2):520-531. (PMID: 28725044)
Blood. 2002 Aug 1;100(3):823-32. (PMID: 12130492)
Curr Protoc Cytom. 2017 Jan 5;79:9.50.1-9.50.11. (PMID: 28055112)
Curr Biol. 1996 Jul 1;6(7):839-47. (PMID: 8805308)
J Leukoc Biol. 2020 Oct;108(4):1379-1395. (PMID: 32930385)
Front Immunol. 2016 May 02;7:166. (PMID: 27199990)
Int J Mol Sci. 2019 Jan 21;20(2):. (PMID: 30669565)
J Immunol Methods. 2017 Nov;450:90-94. (PMID: 28802832)
Blood. 2010 Nov 11;116(19):3865-74. (PMID: 20733159)
Grant Information:
21-74-30016 Russian Science Foundation
Contributed Indexing:
Keywords: HLA-DR; NK cells; adoptive NK cells; genetic modifications; iCasp9 gene; proliferation; retroviral vectors; suicide switch; transduction
Substance Nomenclature:
0 (KIR2DL2 protein, human)
0 (KIR2DL3 protein, human)
0 (KLRC2 protein, human)
0 (NK Cell Lectin-Like Receptor Subfamily C)
0 (Receptors, KIR2DL2)
0 (Receptors, KIR2DL3)
Entry Date(s):
Date Created: 20211224 Date Completed: 20220110 Latest Revision: 20220110
Update Code:
20240104
PubMed Central ID:
PMC8709225
DOI:
10.3390/ijms222413326
PMID:
34948123
Czasopismo naukowe
Nowadays, the use of genetically modified NK cells is a promising strategy for cancer immunotherapy. The additional insertion of genes capable of inducing cell suicide allows for the timely elimination of the modified NK cells. Different subsets of the heterogenic NK cell population may differ in proliferative potential, in susceptibility to genetic viral transduction, and to the subsequent induction of cell death. The CD57 - NKG2C + NK cells are of special interest as potential candidates for therapeutic usage due to their high proliferative potential and certain features of adaptive NK cells. In this study, CD57 - NK cell subsets differing in KIR2DL2/3 and NKG2C expression were transduced with the iCasp9 suicide gene. The highest transduction efficacy was observed in the KIR2DL2/3 + NKG2C + NK cell subset, which demonstrated an increased proliferative potential with prolonged cultivation. The increased transduction efficiency of the cell cultures was associated with the higher expression level of the HLA-DR activation marker. Among the iCasp9-transduced subsets, KIR2DL2/3 + cells had the weakest response to the apoptosis induction by the chemical inductor of dimerization (CID). Thus, KIR2DL2/3 + NKG2C + NK cells showed an increased susceptibility to the iCasp9 retroviral transduction, which was associated with higher proliferative potential and activation status. However, the complete elimination of these cells with CID is impeded.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies